摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-fluorophenyl)-2-[5-(3-isothiocyanatophenyl)-1,3,4-oxadiazol-2-ylsulfanyl]-1-ethanone | 1350302-03-2

中文名称
——
中文别名
——
英文名称
1-(4-fluorophenyl)-2-[5-(3-isothiocyanatophenyl)-1,3,4-oxadiazol-2-ylsulfanyl]-1-ethanone
英文别名
1-(4-Fluorophenyl)-2-[[5-(3-isothiocyanatophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]ethanone
1-(4-fluorophenyl)-2-[5-(3-isothiocyanatophenyl)-1,3,4-oxadiazol-2-ylsulfanyl]-1-ethanone化学式
CAS
1350302-03-2
化学式
C17H10FN3O2S2
mdl
——
分子量
371.416
InChiKey
VTQRCKMBKLAANR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    126
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-溴-4'-氟苯乙酮5-(3-isothiocyanatophenyl)-1,3,4-oxadiazole-2-thiol三乙胺 作用下, 以 丙酮 为溶剂, 反应 2.0h, 以79%的产率得到1-(4-fluorophenyl)-2-[5-(3-isothiocyanatophenyl)-1,3,4-oxadiazol-2-ylsulfanyl]-1-ethanone
    参考文献:
    名称:
    The structure–antituberculosis activity relationships study in a series of 5-aryl-2-thio-1,3,4-oxadiazole derivatives
    摘要:
    A series of 82 5-aryl-2-thio-1,3,4-oxadiazole derivatives were screened for their anti-mycobacterial activities against Mycobacterium tuberculosis H37Rv. The synthesized compounds 30-37 appeared to be the most active derivatives exhibiting more than 90% inhibition of mycobacterial growth at 12.5 mu g/mL. Structure-activity relationships study was performed for the given series by using the electronic-topological method combined with neural networks (ETM-NN). A system for the anti-mycobacterial activity prediction was developed as the result of training associative neural network (ASNN) with weights calculated from projections of a compound and each pharmacophoric fragment found on the elements of the Kohonen's self-organizing maps (SOMs). From the detailed analysis of all compounds under study, the necessary requirements for a compound to possess antituberculosis activity have been formulated. The analysis has shown that any requirement's violation for a molecule implies a considerable decrease or even complete loss of its activity. Molecular docking studies of the compounds allowed shedding light on the binding mode of these novel anti-mycobacterial inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.09.038
点击查看最新优质反应信息

文献信息

  • The structure–antituberculosis activity relationships study in a series of 5-aryl-2-thio-1,3,4-oxadiazole derivatives
    作者:Fliur Macaev、Zinaida Ribkovskaia、Serghei Pogrebnoi、Veaceslav Boldescu、Ghenadie Rusu、Nathaly Shvets、Anatholy Dimoglo、Athina Geronikaki、Robert Reynolds
    DOI:10.1016/j.bmc.2011.09.038
    日期:2011.11
    A series of 82 5-aryl-2-thio-1,3,4-oxadiazole derivatives were screened for their anti-mycobacterial activities against Mycobacterium tuberculosis H37Rv. The synthesized compounds 30-37 appeared to be the most active derivatives exhibiting more than 90% inhibition of mycobacterial growth at 12.5 mu g/mL. Structure-activity relationships study was performed for the given series by using the electronic-topological method combined with neural networks (ETM-NN). A system for the anti-mycobacterial activity prediction was developed as the result of training associative neural network (ASNN) with weights calculated from projections of a compound and each pharmacophoric fragment found on the elements of the Kohonen's self-organizing maps (SOMs). From the detailed analysis of all compounds under study, the necessary requirements for a compound to possess antituberculosis activity have been formulated. The analysis has shown that any requirement's violation for a molecule implies a considerable decrease or even complete loss of its activity. Molecular docking studies of the compounds allowed shedding light on the binding mode of these novel anti-mycobacterial inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
查看更多